canada clinical guidance

Giant cell arteritis (temporal arteritis)

A Canadian clinical summary of giant cell arteritis (temporal arteritis), with source-attributed priorities and explicit jurisdiction boundaries.

JurisdictionCanada
Source check2026-08-20
Clinical reviewiatroX editorial team 路 Clinical editorial review 路 reviewed 2026-08-20 路 due 2027-08-20
AudienceHealthcare professionals practising in Canada
This is an iatroX educational summary of named Canada sources, not an official guideline. It does not replace the complete source documents, local policy, specialist advice or clinical judgement. Alberta is used as an explicit Canadian implementation example, not as a national rule. Verify the equivalent pathway, formulary and escalation route in the patient鈥檚 province or territory.

Alberta source: bounded use

Provincial Giant Cell Arteritis Primary Care Clinical Pathway supplies a Canadian implementation example for this summary. It must not be presented as the rule outside Alberta.
sources for this section:AHS GCA pathway

Source-attributed clinical priorities

  • Treat new visual symptoms, jaw or tongue claudication, ischemic neurologic symptoms or high clinical suspicion as an emergency.
  • Start appropriate glucocorticoid treatment without delaying for confirmatory testing when vision is threatened.
  • Coordinate temporal-artery imaging or biopsy and longitudinal monitoring through the local urgent specialty pathway.
  • Visual ischemic symptoms require same-day specialist coordination even if inflammatory markers are normal.
sources for this section:AHS GCA pathway

Practical assessment and management workflow

1
Ask about new headache, scalp tenderness, jaw or tongue claudication, constitutional symptoms and polymyalgia features.
2
Examine vision, pupils, temporal arteries, pulses and neurologic status and obtain inflammatory and baseline safety tests.
3
Start treatment immediately when clinical suspicion threatens vision, then arrange confirmatory ultrasound or biopsy.
4
Monitor visual and vascular symptoms, inflammatory response, relapse and glucocorticoid toxicity longitudinally.
sources for this section:AHS GCA pathway

Safety, red flags and urgent escalation

  • Do not postpone glucocorticoids for imaging or biopsy when vision is at risk.
  • Escalate transient or permanent visual loss, diplopia, stroke symptoms or limb ischemia immediately.
  • Assess for large-vessel aortitis when symptoms or examination indicate it.
sources for this section:AHS GCA pathway

Confirm the local pathway before acting

Alberta is used as an explicit Canadian implementation example, not as a national rule. Verify the equivalent pathway, formulary and escalation route in the patient鈥檚 province or territory.
sources for this section:AHS GCA pathway

Source and implementation boundary

Read this educational summary with the linked source, current Canadian product information where medicines are involved, and the applicable provincial or territorial pathway. Local formularies, reporting duties, referral routes and service availability can differ.
sources for this section:AHS GCA pathway

Source documents

Use the linked source documents for complete recommendations, evidence grading, exclusions and implementation detail.

  1. Alberta Health ServicesProvincial Giant Cell Arteritis Primary Care Clinical PathwayUpdated 2025-05 路 accessed 2026-08-20
    view source
continue the learning

From guidance to deliberate practice and evidence

Choose what happens next. iatroX can carry this page's jurisdiction, source-check date and released version into an editable learning record, support your reflection, or let you browse the regional question bank while keeping this topic visible. No action records completion, starts a session or awards CPD/CME credit automatically.

Found a source update or regional discrepancy? Tell the iatroX editorial team.